Difference between revisions of "Penile cancer"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "/uL" to "/μL")
m
 
(45 intermediate revisions by 3 users not shown)
Line 3: Line 3:
 
[[#top|Back to Top]]
 
[[#top|Back to Top]]
 
</div>
 
</div>
{{#lst:Section editor transclusions|gu}}
+
{{#lst:Editorial board transclusions|gu}}
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
|-
 
|-
Line 11: Line 11:
 
{{TOC limit|limit=3}}
 
{{TOC limit|limit=3}}
 
=Guidelines=
 
=Guidelines=
==[http://www.esmo.org/ ESMO]==
+
'''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.'''
*'''2013:''' Van Poppel et al. [https://www.esmo.org/Guidelines/Genitourinary-Cancers/Penile-Carcinoma Penile cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up]
+
==EAU/ASCO==
==[https://www.nccn.org/ NCCN]==
+
*'''2023:''' Brouwer et al. [https://doi.org/10.1016/j.eururo.2023.02.027 European Association of Urology-American Society of Clinical Oncology Collaborative Guideline on Penile Cancer: 2023 Update] [https://www.ncbi.nlm.nih.gov/pubmed/36906413 PubMed]
*[https://www.nccn.org/professionals/physician_gls/pdf/penile.pdf NCCN Guidelines - Penile Cancer]
+
 
 +
==[https://www.esmo.org/ ESMO]==
 +
*'''2013:''' Van Poppel et al. [https://www.esmo.org/Guidelines/Genitourinary-Cancers/Penile-Carcinoma Penile cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://www.ncbi.nlm.nih.gov/pubmed/23975666 PubMed]
 +
 
 +
==NCCN==
 +
*[https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1456 NCCN Guidelines - Penile Cancer]
 +
**'''2013:''' Clark et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4042432/ Penile cancer: Clinical Practice Guidelines in Oncology] [https://pubmed.ncbi.nlm.nih.gov/23667209/ PubMed]
 +
 
 
=Neoadjuvant chemotherapy=
 
=Neoadjuvant chemotherapy=
 
==TIP {{#subobject:fe995|Regimen=1}}==
 
==TIP {{#subobject:fe995|Regimen=1}}==
Line 20: Line 27:
 
<div class="toccolours" style="background-color:#eeeeee">
 
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen {{#subobject:b81dfa|Variant=1}}===
 
===Regimen {{#subobject:b81dfa|Variant=1}}===
{| class="wikitable" style="width: 40%; text-align:center;"  
+
{| class="wikitable sortable" style="width: 60%; text-align:center;"  
!style="width: 25%"|Study
+
!style="width: 33%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+
!style="width: 33%"|Dates of enrollment
 +
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
|-
 
|-
 
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2940402/ Pagliaro et al. 2010 (MDACC ID99-194)]
 
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2940402/ Pagliaro et al. 2010 (MDACC ID99-194)]
 +
|2000-04 to 2008-09
 
|style="background-color:#91cf61"|Phase 2
 
|style="background-color:#91cf61"|Phase 2
 
|-
 
|-
 
|}
 
|}
''Note: cycle was repeated on day 22 if the patient's ANC was at least 1400/μL and platelet count was at least 100 x 10<sup>9</sup>/L.''
+
''Note: cycle was repeated on day 22 if the patient's ANC was at least 1400/μL and platelet count was at least 100 x 10<sup>9</sup>/L. Some guidelines state that it is reasonable to give adjuvant TIP if it was not given preoperatively and pathology shows high-risk features, or to give first-line TIP in the metastatic setting; to our knowledge, there are no primary references to support this practice.''
 
<div class="toccolours" style="background-color:#b3e2cd">
 
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
Line 36: Line 45:
 
**Administered intravenously in 250 mL of normal saline containing 12.5 g of mannitol
 
**Administered intravenously in 250 mL of normal saline containing 12.5 g of mannitol
 
====Supportive therapy====
 
====Supportive therapy====
*[[Mesna (Mesnex)]] as follows:
+
*[[Mesna (Mesnex)]] 400 mg/m<sup>2</sup> IV once per day on days 1 to 3, prior to each dose of ifosfamide, then 200 mg/m<sup>2</sup> IV twice per day on days 1 to 3, at 4 and 8 hours after each dose of ifosfamide
**400 mg/m<sup>2</sup> IV once per day on days 1 to 3, prior to each dose of [[Ifosfamide (Ifex)]]
+
*[[:Category:Hydration|hydration]] with 3 liters of a solution of 5% dextrose, sodium chloride, potassium chloride, magnesium sulfate, and mannitol, given after cisplatin
**200 mg/m<sup>2</sup> IV twice per day on days 1 to 3, at 4 and 8 hours after each dose of [[Ifosfamide (Ifex)]]
 
*After [[Cisplatin (Platinol)]], hydration with 3 liters of a solution of 5% dextrose, sodium chloride, potassium chloride, magnesium sulfate, and mannitol
 
 
*One of the following dexamethasone doses:
 
*One of the following dexamethasone doses:
**[[Dexamethasone (Decadron)]] 8 mg IV once 1 hour before [[Paclitaxel (Taxol)]]
+
**[[Dexamethasone (Decadron)]] 8 mg IV once 1 hour prior to paclitaxel
**[[Dexamethasone (Decadron)]] 20 mg PO given twice, at 12 and 6 hours before [[Paclitaxel (Taxol)]]
+
**[[Dexamethasone (Decadron)]] 20 mg PO given twice, at 12 and 6 hours prior to paclitaxel
*[[Diphenhydramine (Benadryl)]] 50 mg IV once on day 1, prior to [[Paclitaxel (Taxol)]]
+
*[[Diphenhydramine (Benadryl)]] 50 mg IV once on day 1, prior to paclitaxel
 
*One of the following H2 blockers:
 
*One of the following H2 blockers:
**[[Cimetidine (Tagamet)]] 300 mg IV once on day 1, prior to [[Paclitaxel (Taxol)]]
+
**[[Cimetidine (Tagamet)]] 300 mg IV once on day 1, prior to paclitaxel
**[[Ranitidine (Zantac)]] 50 mg IV once on day 1, prior to [[Paclitaxel (Taxol)]]
+
**[[Ranitidine (Zantac)]] 50 mg IV once on day 1, prior to paclitaxel
**[[Famotidine (Pepcid)]] 20 mg IV once on day 1, prior to [[Paclitaxel (Taxol)]]
+
**[[Famotidine (Pepcid)]] 20 mg IV once on day 1, prior to paclitaxel
 
*"The use of prophylactic G-CSF was allowed but not required"
 
*"The use of prophylactic G-CSF was allowed but not required"
 
'''21- to 28-day cycle for 4 cycles'''
 
'''21- to 28-day cycle for 4 cycles'''
Line 55: Line 62:
 
*[[Surgery#Surgical_resection|Surgery]]
 
*[[Surgery#Surgical_resection|Surgery]]
 
</div></div>
 
</div></div>
 +
 
===References===
 
===References===
# '''MDACC ID99-194:''' Pagliaro LC, Williams DL, Daliani D, Williams MB, Osai W, Kincaid M, Wen S, Thall PF, Pettaway CA. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol. 2010 Aug 20;28(24):3851-7. Epub 2010 Jul 12. [https://doi.org/10.1200/jco.2010.29.5477 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2940402/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/20625118 PubMed] NCT00512096
+
# '''MDACC ID99-194:''' Pagliaro LC, Williams DL, Daliani D, Williams MB, Osai W, Kincaid M, Wen S, Thall PF, Pettaway CA. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol. 2010 Aug 20;28(24):3851-7. Epub 2010 Jul 12. [https://doi.org/10.1200/jco.2010.29.5477 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2940402/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/20625118/ PubMed] [https://clinicaltrials.gov/study/NCT00512096 NCT00512096]
 
==VBM (Vincristine) {{#subobject:fdb0db|Regimen=1}}==
 
==VBM (Vincristine) {{#subobject:fdb0db|Regimen=1}}==
 
VBM: '''<u>V</u>'''incristine, '''<u>B</u>'''leomycin, '''<u>M</u>'''ethotrexate
 
VBM: '''<u>V</u>'''incristine, '''<u>B</u>'''leomycin, '''<u>M</u>'''ethotrexate
<div class="toccolours" style="background-color:#eeeeee">
+
<div class="toccolours" style="background-color:#ee6b6e">
 
===Regimen {{#subobject:a25051|Variant=1}}===
 
===Regimen {{#subobject:a25051|Variant=1}}===
{| class="wikitable" style="width: 40%; text-align:center;"  
+
{| class="wikitable sortable" style="width: 60%; text-align:center;"  
!style="width: 25%"|Study
+
!style="width: 33%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+
!style="width: 33%"|Dates of enrollment
 +
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
|-
 
|-
|[http://www.tandfonline.com/doi/full/10.3109/02841868809094366 Pizzocaro et al. 1988]
+
|[https://doi.org/10.3109/02841868809094366 Pizzocaro et al. 1988]
|style="background-color:#ffffbe"|Pilot, <20 pts
+
|1979-1985
 +
|style="background-color:#ffffbe"|Pilot, fewer than 20 pts
 
|-
 
|-
 
|}
 
|}
Line 76: Line 86:
 
<div class="toccolours" style="background-color:#b3e2cd">
 
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
*[[Vincristine (Oncovin)]] 1 mg IV once per day on days 1, 8, 15
+
*[[Vincristine (Oncovin)]] 1 mg IV once on day 1
*[[Bleomycin (Blenoxane)]] 15 mg IM once per day on days 1, 2, 8, 9, 15, 16, '''given 6 hours and 24 hours after vincristine'''
+
*[[Bleomycin (Blenoxane)]] 15 mg IM once per day on days 1 & 2, '''given 6 hours and 24 hours after vincristine'''
*[[Methotrexate (MTX)]] 30 mg PO once per day on days 3, 10, 17, '''given 48 hours after vincristine'''
+
*[[Methotrexate (MTX)]] 30 mg PO once on days 3, '''given 48 hours after vincristine'''
'''21-day cycle for 4 cycles'''
+
'''7-day cycle for 12 cycles'''
 
</div>
 
</div>
 
<div class="toccolours" style="background-color:#cbd5e7">
 
<div class="toccolours" style="background-color:#cbd5e7">
Line 86: Line 96:
 
</div></div>
 
</div></div>
 
===References===
 
===References===
# Pizzocaro G, Piva L. Adjuvant and neoadjuvant vincristine, bleomycin, and methotrexate for inguinal metastases from squamous cell carcinoma of the penis. Acta Oncol. 1988;27(6b):823-4. [http://www.tandfonline.com/doi/full/10.3109/02841868809094366 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/2466471 PubMed]  
+
# Pizzocaro G, Piva L. Adjuvant and neoadjuvant vincristine, bleomycin, and methotrexate for inguinal metastases from squamous cell carcinoma of the penis. Acta Oncol. 1988;27(6b):823-4. [https://doi.org/10.3109/02841868809094366 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/2466471/ PubMed]  
# '''Review:''' Pagliaro LC, Crook J. Multimodality therapy in penile cancer: when and which treatments? World J Urol. 2009 Apr;27(2):221-5. Epub 2008 Aug 6. [http://link.springer.com/article/10.1007/s00345-008-0310-z link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164341/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/18682961 PubMed]
+
# '''Review:''' Pagliaro LC, Crook J. Multimodality therapy in penile cancer: when and which treatments? World J Urol. 2009 Apr;27(2):221-5. Epub 2008 Aug 6. [https://doi.org/10.1007/s00345-008-0310-z link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164341/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/18682961/ PubMed]
 
=Adjuvant chemotherapy=
 
=Adjuvant chemotherapy=
 
==DCF {{#subobject:118691|Regimen=1}}==
 
==DCF {{#subobject:118691|Regimen=1}}==
Line 113: Line 123:
 
</div></div>
 
</div></div>
 
===References===
 
===References===
# '''Case report:''' Necchi A, Nicolai N, Colecchia M, Catanzaro M, Torelli T, Piva L, Salvioni R. Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis. J Clin Oncol. 2011 Aug 1;29(22):e650-2. Epub 2011 May 31. [https://doi.org/10.1200/jco.2011.34.8367 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/21632506 PubMed]
+
# '''Case report:''' Necchi A, Nicolai N, Colecchia M, Catanzaro M, Torelli T, Piva L, Salvioni R. Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis. J Clin Oncol. 2011 Aug 1;29(22):e650-2. Epub 2011 May 31. [https://doi.org/10.1200/jco.2011.34.8367 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/21632506/ PubMed]
==TIP==
+
 
TIP: '''<u>T</u>'''axol (Paclitaxel), '''<u>I</u>'''fosfamide, '''<u>P</u>'''latinol (Cisplatin)
 
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen===
 
<br>''Note: No primary reference available, but some guidelines state that it is reasonable to give adjuvant TIP if it was not given preoperatively and pathology shows high-risk features. (see neoadjuvant [[#TIP|TIP for a referenced regimen]])''
 
<div class="toccolours" style="background-color:#cbd5e8">
 
====Preceding treatment====
 
*[[Surgery#Surgical_resection|Surgery]]
 
</div>
 
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
*[[Paclitaxel (Taxol)]]
 
*[[Ifosfamide (Ifex)]]
 
*[[Cisplatin (Platinol)]]
 
</div></div>
 
===References===
 
#No primary reference available
 
 
=Metastatic or unresectable disease=
 
=Metastatic or unresectable disease=
 
==BMP {{#subobject:ab9e5f|Regimen=1}}==
 
==BMP {{#subobject:ab9e5f|Regimen=1}}==
 
BMP: '''<u>B</u>'''leomycin, '''<u>M</u>'''ethotrexate, '''<u>P</u>'''latinol (Cisplatin)
 
BMP: '''<u>B</u>'''leomycin, '''<u>M</u>'''ethotrexate, '''<u>P</u>'''latinol (Cisplatin)
 
<br>MPB: '''<u>M</u>'''ethotrexate, '''<u>P</u>'''latinol (Cisplatin), '''<u>B</u>'''leomycin
 
<br>MPB: '''<u>M</u>'''ethotrexate, '''<u>P</u>'''latinol (Cisplatin), '''<u>B</u>'''leomycin
<div class="toccolours" style="background-color:#eeeeee">
+
<div class="toccolours" style="background-color:#ee6b6e">
 
===Regimen variant #1 {{#subobject:8938|Variant=1}}===
 
===Regimen variant #1 {{#subobject:8938|Variant=1}}===
{| class="wikitable" style="width: 40%; text-align:center;"  
+
{| class="wikitable sortable" style="width: 60%; text-align:center;"  
!style="width: 25%"|Study
+
!style="width: 33%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+
!style="width: 33%"|Dates of enrollment
 +
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
|-
 
|-
|[http://www.auajournals.org/article/S0022-5347(05)68815-5 Haas et al. 1999 (SWOG 8520)]
+
|[https://doi.org/10.1016/S0022-5347(05)68815-5 Haas et al. 1999 (SWOG 8520)]
 +
|1986-1994
 
|style="background-color:#91cf61"|Phase 2
 
|style="background-color:#91cf61"|Phase 2
 
|-
 
|-
Line 153: Line 149:
 
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1, given at a rate of 1 mg/min
 
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1, given at a rate of 1 mg/min
 
====Supportive therapy====
 
====Supportive therapy====
*Normal saline IV at 250 mL/hour, starting 1 hour before [[Cisplatin (Platinol)]] and continued for at least 6 hours after completion of [[Cisplatin (Platinol)]]
+
*Normal saline IV at 250 mL/hour, starting 1 hour prior to cisplatin and continued for at least 6 hours after completion of cisplatin
*[[Furosemide (Lasix)]] 40 mg IV once on day 1, given prior to [[Cisplatin (Platinol)]]
+
*[[Furosemide (Lasix)]] 40 mg IV once on day 1, given prior to cisplatin
 
'''21-day cycles (patients who achieved CR discontinued therapy after 6 cycles)'''
 
'''21-day cycles (patients who achieved CR discontinued therapy after 6 cycles)'''
 
</div></div><br>
 
</div></div><br>
<div class="toccolours" style="background-color:#eeeeee">
+
<div class="toccolours" style="background-color:#ee6b6e">
 
===Regimen variant #2 {{#subobject:99e731|Variant=1}}===
 
===Regimen variant #2 {{#subobject:99e731|Variant=1}}===
{| class="wikitable" style="width: 40%; text-align:center;"  
+
{| class="wikitable sortable" style="width: 60%; text-align:center;"  
!style="width: 25%"|Study
+
!style="width: 33%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+
!style="width: 33%"|Dates of enrollment
 +
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
|-
 
|-
|[http://www.auajournals.org/article/S0022-5347%2801)62402-9 Corral et al. 1998]
+
|[https://doi.org/10.1016/S0022-5347(01)62402-9 Corral et al. 1998]
 +
|1988-03 to 1994-01
 
|style="background-color:#91cf61"|Phase 2
 
|style="background-color:#91cf61"|Phase 2
 
|-
 
|-
Line 176: Line 174:
 
**Note: Corral et al. 1998 does not specify which days cisplatin is given on. Pagliaro et al. 2009 specifies that cisplatin is given on days 2 to 6. For Corral et al. 1998, the 5 day course is inferred based on the paper saying that the total dosage--presumably per cycle--was 100 mg/m<sup>2</sup>.
 
**Note: Corral et al. 1998 does not specify which days cisplatin is given on. Pagliaro et al. 2009 specifies that cisplatin is given on days 2 to 6. For Corral et al. 1998, the 5 day course is inferred based on the paper saying that the total dosage--presumably per cycle--was 100 mg/m<sup>2</sup>.
 
====Supportive therapy====
 
====Supportive therapy====
*[[Folinic acid (Leucovorin)]] 25 mg PO every 6 hours on days 2 to 4, 16 to 18, 23 to 25, starting 24 hours after each dose of [[Methotrexate (MTX)]]
+
*[[Leucovorin (Folinic acid)]] 25 mg PO every 6 hours on days 2 to 4, 16 to 18, 23 to 25, starting 24 hours after each dose of methotrexate
 
'''28-day cycles'''
 
'''28-day cycles'''
 
</div></div>
 
</div></div>
 
===References===
 
===References===
# Corral DA, Sella A, Pettaway CA, Amato RJ, Jones DM, Ellerhorst J. Combination chemotherapy for metastatic or locally advanced genitourinary squamous cell carcinoma: a phase II study of methotrexate, cisplatin and bleomycin. J Urol. 1998 Nov;160(5):1770-4. [http://www.auajournals.org/article/S0022-5347%2801)62402-9 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/9783949 PubMed]
+
# Corral DA, Sella A, Pettaway CA, Amato RJ, Jones DM, Ellerhorst J. Combination chemotherapy for metastatic or locally advanced genitourinary squamous cell carcinoma: a phase II study of methotrexate, cisplatin and bleomycin. J Urol. 1998 Nov;160(5):1770-4. [https://doi.org/10.1016/S0022-5347(01)62402-9 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/9783949/ PubMed]
# Haas GP, Blumenstein BA, Gagliano RG, Russell CA, Rivkin SE, Culkin DJ, Wolf M, Crawford ED. Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: a Southwest Oncology Group study. J Urol. 1999 Jun;161(6):1823-5. [http://www.auajournals.org/article/S0022-5347(05)68815-5 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/10332445 PubMed] content property of [http://hemonc.org HemOnc.org]
+
# '''SWOG 8520:''' Haas GP, Blumenstein BA, Gagliano RG, Russell CA, Rivkin SE, Culkin DJ, Wolf M, Crawford ED. Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: a Southwest Oncology Group study. J Urol. 1999 Jun;161(6):1823-5. [https://doi.org/10.1016/S0022-5347(05)68815-5 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/10332445/ PubMed] content property of [https://hemonc.org HemOnc.org]
# '''Review:''' Pagliaro LC, Crook J. Multimodality therapy in penile cancer: when and which treatments? World J Urol. 2009 Apr;27(2):221-5. Epub 2008 Aug 6. [http://link.springer.com/article/10.1007/s00345-008-0310-z link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164341/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/18682961 PubMed]
+
# '''Review:''' Pagliaro LC, Crook J. Multimodality therapy in penile cancer: when and which treatments? World J Urol. 2009 Apr;27(2):221-5. Epub 2008 Aug 6. [https://doi.org/10.1007/s00345-008-0310-z link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164341/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/18682961/ PubMed]
 +
 
 
==Cisplatin & Fluorouracil (CF) {{#subobject:f70357|Regimen=1}}==
 
==Cisplatin & Fluorouracil (CF) {{#subobject:f70357|Regimen=1}}==
 
<div class="toccolours" style="background-color:#eeeeee">
 
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen {{#subobject:1e2b1c|Variant=1}}===
 
===Regimen {{#subobject:1e2b1c|Variant=1}}===
{| class="wikitable" style="width: 40%; text-align:center;"  
+
{| class="wikitable sortable" style="width: 60%; text-align:center;"  
!style="width: 25%"|Study
+
!style="width: 33%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+
!style="width: 33%"|Dates of enrollment
 +
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
|-
 
|-
 
|[https://doi.org/10.1016/s0022-5347(17)37327-5 Shammas et al. 1992]
 
|[https://doi.org/10.1016/s0022-5347(17)37327-5 Shammas et al. 1992]
|style="background-color:#ffffbe"|Pilot, <20 pts
+
|1985-1990
 +
|style="background-color:#ffffbe"|Pilot, fewer than 20 pts
 
|-
 
|-
 
|}
 
|}
Line 200: Line 201:
 
</div></div>
 
</div></div>
 
===References===
 
===References===
# Shammas FV, Ous S, Fossa SD. Cisplatin and 5-fluorouracil in advanced cancer of the penis. J Urol. 1992 Mar;147(3):630-2. [https://doi.org/10.1016/s0022-5347(17)37327-5 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/1538445 PubMed]
+
# Shammas FV, Ous S, Fossa SD. Cisplatin and 5-fluorouracil in advanced cancer of the penis. J Urol. 1992 Mar;147(3):630-2. [https://doi.org/10.1016/s0022-5347(17)37327-5 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/1538445/ PubMed]
 
==Cisplatin & Irinotecan (IC) {{#subobject:606813|Regimen=1}}==
 
==Cisplatin & Irinotecan (IC) {{#subobject:606813|Regimen=1}}==
 
<div class="toccolours" style="background-color:#eeeeee">
 
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen {{#subobject:ec3985|Variant=1}}===
 
===Regimen {{#subobject:ec3985|Variant=1}}===
{| class="wikitable" style="width: 40%; text-align:center;"  
+
{| class="wikitable sortable" style="width: 60%; text-align:center;"  
!style="width: 25%"|Study
+
!style="width: 33%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+
!style="width: 33%"|Dates of enrollment
 +
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
|-
 
|-
 
|[https://doi.org/10.1093/annonc/mdn149 Theodore et al. 2008 (EORTC 30992)]
 
|[https://doi.org/10.1093/annonc/mdn149 Theodore et al. 2008 (EORTC 30992)]
 +
|2004-05 to 2006-01
 
|style="background-color:#91cf61"|Phase 2
 
|style="background-color:#91cf61"|Phase 2
 
|-
 
|-
Line 217: Line 220:
 
*[[Irinotecan (Camptosar)]] 60 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1, 8, 15, '''given first'''
 
*[[Irinotecan (Camptosar)]] 60 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1, 8, 15, '''given first'''
 
====Supportive therapy====
 
====Supportive therapy====
*Adequate hydration with cisplatin, per guidelines at each investigator's site
+
*Adequate [[:Category:Hydration|hydration]] with cisplatin, per guidelines at each investigator's site
 
*Antiemetic medication per routine local practice.  
 
*Antiemetic medication per routine local practice.  
 
*"Systematic premedication with atropine as of the first cycle of treatment was at the investigator's discretion but was not recommended."
 
*"Systematic premedication with atropine as of the first cycle of treatment was at the investigator's discretion but was not recommended."
Line 223: Line 226:
 
</div></div>
 
</div></div>
 
===References===
 
===References===
# Theodore C, Skoneczna I, Bodrogi I, Leahy M, Kerst JM, Collette L, Ven K, Marréaud S, Oliver RD; [[Study_Groups#EORTC|EORTC]] Genito-Urinary Tract Cancer Group. A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992). Ann Oncol. 2008 Jul;19(7):1304-7. [https://doi.org/10.1093/annonc/mdn149 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/18417462 PubMed]
+
# '''EORTC 30992:''' Theodore C, Skoneczna I, Bodrogi I, Leahy M, Kerst JM, Collette L, Ven K, Marréaud S, Oliver RD; [[Study_Groups#EORTC|EORTC]] Genito-Urinary Tract Cancer Group. A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992). Ann Oncol. 2008 Jul;19(7):1304-7. Epub 2008 Apr 15. [https://doi.org/10.1093/annonc/mdn149 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/18417462/ PubMed]
 +
 
 
==Paclitaxel monotherapy {{#subobject:3bde8f|Regimen=1}}==
 
==Paclitaxel monotherapy {{#subobject:3bde8f|Regimen=1}}==
 
<div class="toccolours" style="background-color:#eeeeee">
 
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen {{#subobject:2565c5|Variant=1}}===
 
===Regimen {{#subobject:2565c5|Variant=1}}===
{| class="wikitable" style="width: 40%; text-align:center;"  
+
{| class="wikitable sortable" style="width: 60%; text-align:center;"  
!style="width: 25%"|Study
+
!style="width: 33%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+
!style="width: 33%"|Dates of enrollment
 +
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
|-
 
|-
 
|[https://doi.org/10.1016/j.eururo.2011.08.028 Di Lorenzo et al. 2011]
 
|[https://doi.org/10.1016/j.eururo.2011.08.028 Di Lorenzo et al. 2011]
 +
|2004-04 to 2011-01
 
|style="background-color:#91cf61"|Phase 2
 
|style="background-color:#91cf61"|Phase 2
 
|-
 
|-
Line 244: Line 250:
 
</div></div>
 
</div></div>
 
===References===
 
===References===
# Di Lorenzo G, Federico P, Buonerba C, Longo N, Cartenì G, Autorino R, Perdonà S, Ferro M, Rescigno P, D'Aniello C, Matano E, Altieri V, Palmieri G, Imbimbo C, De Placido S, Mirone V. Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study. Eur Urol. 2011 Dec;60(6):1280-4. [https://doi.org/10.1016/j.eururo.2011.08.028 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/21871710 PubMed]
+
# Di Lorenzo G, Federico P, Buonerba C, Longo N, Cartenì G, Autorino R, Perdonà S, Ferro M, Rescigno P, D'Aniello C, Matano E, Altieri V, Palmieri G, Imbimbo C, De Placido S, Mirone V. Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study. Eur Urol. 2011 Dec;60(6):1280-4. Epub 2011 Aug 22. [https://doi.org/10.1016/j.eururo.2011.08.028 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/21871710/ PubMed]
 +
 
 
==Panitumumab monotherapy {{#subobject:92a67f|Regimen=1}}==
 
==Panitumumab monotherapy {{#subobject:92a67f|Regimen=1}}==
 
<div class="toccolours" style="background-color:#eeeeee">
 
<div class="toccolours" style="background-color:#eeeeee">
Line 262: Line 269:
 
</div></div>
 
</div></div>
 
===References===
 
===References===
# '''Case report:''' Necchi A, Nicolai N, Colecchia M, Catanzaro M, Torelli T, Piva L, Salvioni R. Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis. J Clin Oncol. 2011 Aug 1;29(22):e650-2. Epub 2011 May 31. [https://doi.org/10.1200/jco.2011.34.8367 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/21632506 PubMed]
+
# '''Case report:''' Necchi A, Nicolai N, Colecchia M, Catanzaro M, Torelli T, Piva L, Salvioni R. Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis. J Clin Oncol. 2011 Aug 1;29(22):e650-2. Epub 2011 May 31. [https://doi.org/10.1200/jco.2011.34.8367 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/21632506/ PubMed]
 
==PCF {{#subobject:edc2a7|Regimen=1}}==
 
==PCF {{#subobject:edc2a7|Regimen=1}}==
 
PCF: '''<u>P</u>'''aclitaxel, '''<u>C</u>'''isplatin, '''<u>F</u>'''luorouracil
 
PCF: '''<u>P</u>'''aclitaxel, '''<u>C</u>'''isplatin, '''<u>F</u>'''luorouracil
 
<div class="toccolours" style="background-color:#eeeeee">
 
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen {{#subobject:5f8356|Variant=1}}===
 
===Regimen {{#subobject:5f8356|Variant=1}}===
{| class="wikitable" style="width: 40%; text-align:center;"  
+
{| class="wikitable sortable" style="width: 60%; text-align:center;"  
!style="width: 25%"|Study
+
!style="width: 33%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+
!style="width: 33%"|Dates of enrollment
 +
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
|-
 
|-
 
|[https://doi.org/10.1016/j.eururo.2008.07.014 Pizzocaro et al. 2009]
 
|[https://doi.org/10.1016/j.eururo.2008.07.014 Pizzocaro et al. 2009]
|style="background-color:#ffffbe"|Pilot, <20 pts
+
|2004-2006
 +
|style="background-color:#ffffbe"|Pilot, fewer than 20 pts
 
|-
 
|-
 
|}
 
|}
Line 282: Line 291:
 
====Supportive therapy====
 
====Supportive therapy====
 
*"Corticosteroids, antihistamines, and an H2 antagonist were administered before starting paclitaxel"
 
*"Corticosteroids, antihistamines, and an H2 antagonist were administered before starting paclitaxel"
*"Antiemetic drugs and glutathione were administered before [[Cisplatin (Platinol)]]"
+
*"Antiemetic drugs and glutathione were administered prior to cisplatin"
*1 liter half normal 2.5% glucose saline with 20 mEq potassium chloride and 10 mEq magnesium sulfate (MgSO4) IV given twice, before and after [[Cisplatin (Platinol)]]
+
*1 liter half normal 2.5% glucose saline with 20 mEq potassium chloride and 10 mEq magnesium sulfate (MgSO4) IV given twice, before and after cisplatin
 
'''21-day cycles'''; "two patients received more than the standard four courses"
 
'''21-day cycles'''; "two patients received more than the standard four courses"
 
</div></div>
 
</div></div>
 
===References===
 
===References===
# Pizzocaro G, Nicolai N, Milani A. Taxanes in combination with cisplatin and fluorouracil for advanced penile cancer: preliminary results. Eur Urol. 2009 Mar;55(3):546-51. Epub 2008 Jul 14. [https://doi.org/10.1016/j.eururo.2008.07.014 link to original article] [https://pubmed.ncbi.nlm.nih.gov/18649992 PubMed]
+
# Pizzocaro G, Nicolai N, Milani A. Taxanes in combination with cisplatin and fluorouracil for advanced penile cancer: preliminary results. Eur Urol. 2009 Mar;55(3):546-51. Epub 2008 Jul 14. [https://doi.org/10.1016/j.eururo.2008.07.014 link to original article] [https://pubmed.ncbi.nlm.nih.gov/18649992/ PubMed]
==TIP {{#subobject:2169d9|Regimen=1}}==
+
 
TIP: '''<u>T</u>'''axol (Paclitaxel), '''<u>I</u>'''fosfamide, '''<u>P</u>'''latinol (Cisplatin)
 
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen===
 
<br>''Note: No primary reference available, but some guidelines state that it is reasonable to give TIP as first-line therapy for metastatic penile cancer (see neoadjuvant [[#TIP|TIP for a referenced regimen]])''
 
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
*[[Paclitaxel (Taxol)]]
 
*[[Ifosfamide (Ifex)]]
 
*[[Cisplatin (Platinol)]]
 
</div></div>
 
===References===
 
# No primary reference available
 
 
[[Category:Penile cancer regimens]]
 
[[Category:Penile cancer regimens]]
 
[[Category:Disease-specific pages]]
 
[[Category:Disease-specific pages]]
[[Category:Genitourinary cancers]]
+
[[Category:Male genital cancers]]

Latest revision as of 21:32, 29 June 2024

Section editor
Alikhaki.jpg
Ali Raza Khaki, MD
Stanford University
Palo Alto, CA, USA

LinkedIn
9 regimens on this page
10 variants on this page


Guidelines

Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.

EAU/ASCO

ESMO

NCCN

Neoadjuvant chemotherapy

TIP

TIP: Taxol (Paclitaxel), Ifosfamide, Platinol (Cisplatin)

Regimen

Study Dates of enrollment Evidence
Pagliaro et al. 2010 (MDACC ID99-194) 2000-04 to 2008-09 Phase 2

Note: cycle was repeated on day 22 if the patient's ANC was at least 1400/μL and platelet count was at least 100 x 109/L. Some guidelines state that it is reasonable to give adjuvant TIP if it was not given preoperatively and pathology shows high-risk features, or to give first-line TIP in the metastatic setting; to our knowledge, there are no primary references to support this practice.

Chemotherapy

  • Paclitaxel (Taxol) 175 mg/m2 IV over 3 hours once on day 1
  • Ifosfamide (Ifex) 1200 mg/m2 IV over 2 hours once per day on days 1 to 3
  • Cisplatin (Platinol) 25 mg/m2 IV over 2 hours once per day on days 1 to 3
    • Administered intravenously in 250 mL of normal saline containing 12.5 g of mannitol

Supportive therapy

  • Mesna (Mesnex) 400 mg/m2 IV once per day on days 1 to 3, prior to each dose of ifosfamide, then 200 mg/m2 IV twice per day on days 1 to 3, at 4 and 8 hours after each dose of ifosfamide
  • hydration with 3 liters of a solution of 5% dextrose, sodium chloride, potassium chloride, magnesium sulfate, and mannitol, given after cisplatin
  • One of the following dexamethasone doses:
  • Diphenhydramine (Benadryl) 50 mg IV once on day 1, prior to paclitaxel
  • One of the following H2 blockers:
  • "The use of prophylactic G-CSF was allowed but not required"

21- to 28-day cycle for 4 cycles

Subsequent treatment

References

  1. MDACC ID99-194: Pagliaro LC, Williams DL, Daliani D, Williams MB, Osai W, Kincaid M, Wen S, Thall PF, Pettaway CA. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol. 2010 Aug 20;28(24):3851-7. Epub 2010 Jul 12. link to original article contains dosing details in manuscript link to PMC article PubMed NCT00512096

VBM (Vincristine)

VBM: Vincristine, Bleomycin, Methotrexate

Regimen

Study Dates of enrollment Evidence
Pizzocaro et al. 1988 1979-1985 Pilot, fewer than 20 pts

Note: this is of historic interest given the toxicity of bleomycin-containing regimens.

Preceding treatment

Chemotherapy

7-day cycle for 12 cycles

Subsequent treatment

References

  1. Pizzocaro G, Piva L. Adjuvant and neoadjuvant vincristine, bleomycin, and methotrexate for inguinal metastases from squamous cell carcinoma of the penis. Acta Oncol. 1988;27(6b):823-4. link to original article contains dosing details in manuscript PubMed
  2. Review: Pagliaro LC, Crook J. Multimodality therapy in penile cancer: when and which treatments? World J Urol. 2009 Apr;27(2):221-5. Epub 2008 Aug 6. link to original article contains dosing details in manuscript link to PMC article PubMed

Adjuvant chemotherapy

DCF

DCF: Docetaxel, Cisplatin, Fluorouracil

Regimen

Study Evidence
Necchi et al. 2011 Case report

Preceding treatment

Chemotherapy

21-day cycle for 3 cycles

References

  1. Case report: Necchi A, Nicolai N, Colecchia M, Catanzaro M, Torelli T, Piva L, Salvioni R. Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis. J Clin Oncol. 2011 Aug 1;29(22):e650-2. Epub 2011 May 31. link to original article contains dosing details in manuscript PubMed

Metastatic or unresectable disease

BMP

BMP: Bleomycin, Methotrexate, Platinol (Cisplatin)
MPB: Methotrexate, Platinol (Cisplatin), Bleomycin

Regimen variant #1

Study Dates of enrollment Evidence
Haas et al. 1999 (SWOG 8520) 1986-1994 Phase 2

Note: This is likely of historic interest due to the toxicity of bleomycin-containing regimens. Bleomycin was discontinued when a total cumulative dose of 200 units/m2 was reached.

Chemotherapy

Supportive therapy

  • Normal saline IV at 250 mL/hour, starting 1 hour prior to cisplatin and continued for at least 6 hours after completion of cisplatin
  • Furosemide (Lasix) 40 mg IV once on day 1, given prior to cisplatin

21-day cycles (patients who achieved CR discontinued therapy after 6 cycles)


Regimen variant #2

Study Dates of enrollment Evidence
Corral et al. 1998 1988-03 to 1994-01 Phase 2

Note: 21 of 29 evaluable patients in Corral et al. 1998 had penile cancer. Please see the paper for additional variations in the protocol, including some patients being treated with intraarterial therapy. This is likely of historic interest due to the toxicity of bleomycin-containing regimens.

Chemotherapy

  • Bleomycin (Blenoxane) 10 mg/m2 IV once per day on days 2 to 6
    • Note: Pagliaro et al. 2009 lists a "dosage of 50 mg/m2 on days 2 to 6," which could be misinterpreted as 50 mg/m2 for each dose, which is in contrast to the 50 mg/m2 for each cycle that Corral et al. 1998 describes.
  • Methotrexate (MTX) 200 mg/m2 IV once per day on days 1, 15, 22
  • Cisplatin (Platinol) 20 mg/m2 IV over 3 hours once per day on days 2 to 6
    • Note: Corral et al. 1998 does not specify which days cisplatin is given on. Pagliaro et al. 2009 specifies that cisplatin is given on days 2 to 6. For Corral et al. 1998, the 5 day course is inferred based on the paper saying that the total dosage--presumably per cycle--was 100 mg/m2.

Supportive therapy

  • Leucovorin (Folinic acid) 25 mg PO every 6 hours on days 2 to 4, 16 to 18, 23 to 25, starting 24 hours after each dose of methotrexate

28-day cycles

References

  1. Corral DA, Sella A, Pettaway CA, Amato RJ, Jones DM, Ellerhorst J. Combination chemotherapy for metastatic or locally advanced genitourinary squamous cell carcinoma: a phase II study of methotrexate, cisplatin and bleomycin. J Urol. 1998 Nov;160(5):1770-4. link to original article contains dosing details in manuscript PubMed
  2. SWOG 8520: Haas GP, Blumenstein BA, Gagliano RG, Russell CA, Rivkin SE, Culkin DJ, Wolf M, Crawford ED. Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: a Southwest Oncology Group study. J Urol. 1999 Jun;161(6):1823-5. link to original article contains dosing details in manuscript PubMed content property of HemOnc.org
  3. Review: Pagliaro LC, Crook J. Multimodality therapy in penile cancer: when and which treatments? World J Urol. 2009 Apr;27(2):221-5. Epub 2008 Aug 6. link to original article contains dosing details in manuscript link to PMC article PubMed

Cisplatin & Fluorouracil (CF)

Regimen

Study Dates of enrollment Evidence
Shammas et al. 1992 1985-1990 Pilot, fewer than 20 pts

Chemotherapy

References

  1. Shammas FV, Ous S, Fossa SD. Cisplatin and 5-fluorouracil in advanced cancer of the penis. J Urol. 1992 Mar;147(3):630-2. link to original article contains dosing details in abstract PubMed

Cisplatin & Irinotecan (IC)

Regimen

Study Dates of enrollment Evidence
Theodore et al. 2008 (EORTC 30992) 2004-05 to 2006-01 Phase 2

Chemotherapy

Supportive therapy

  • Adequate hydration with cisplatin, per guidelines at each investigator's site
  • Antiemetic medication per routine local practice.
  • "Systematic premedication with atropine as of the first cycle of treatment was at the investigator's discretion but was not recommended."

28-day cycles, with up to 4 cycles before surgery in the neoadjuvant setting for T3 or N1 to N2; up to 8 cycles for patients with T4, N3, or M+ distant metastatic disease

References

  1. EORTC 30992: Theodore C, Skoneczna I, Bodrogi I, Leahy M, Kerst JM, Collette L, Ven K, Marréaud S, Oliver RD; EORTC Genito-Urinary Tract Cancer Group. A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992). Ann Oncol. 2008 Jul;19(7):1304-7. Epub 2008 Apr 15. link to original article contains dosing details in manuscript PubMed

Paclitaxel monotherapy

Regimen

Study Dates of enrollment Evidence
Di Lorenzo et al. 2011 2004-04 to 2011-01 Phase 2

Chemotherapy

Supportive therapy

  • G-CSF could be used in later cycles if the patient developed febrile neutropenia during treatment
  • Dexamethasone (Decadron) 8 mg PO given three times, at 12 hours before, immediately before, and 12 hours after paclitaxel

21-day cycles

References

  1. Di Lorenzo G, Federico P, Buonerba C, Longo N, Cartenì G, Autorino R, Perdonà S, Ferro M, Rescigno P, D'Aniello C, Matano E, Altieri V, Palmieri G, Imbimbo C, De Placido S, Mirone V. Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study. Eur Urol. 2011 Dec;60(6):1280-4. Epub 2011 Aug 22. link to original article contains dosing details in manuscript PubMed

Panitumumab monotherapy

Regimen

Study Evidence
Necchi et al. 2011 Case report

Targeted therapy

14-day cycles

References

  1. Case report: Necchi A, Nicolai N, Colecchia M, Catanzaro M, Torelli T, Piva L, Salvioni R. Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis. J Clin Oncol. 2011 Aug 1;29(22):e650-2. Epub 2011 May 31. link to original article contains dosing details in manuscript PubMed

PCF

PCF: Paclitaxel, Cisplatin, Fluorouracil

Regimen

Study Dates of enrollment Evidence
Pizzocaro et al. 2009 2004-2006 Pilot, fewer than 20 pts

Chemotherapy

Supportive therapy

  • "Corticosteroids, antihistamines, and an H2 antagonist were administered before starting paclitaxel"
  • "Antiemetic drugs and glutathione were administered prior to cisplatin"
  • 1 liter half normal 2.5% glucose saline with 20 mEq potassium chloride and 10 mEq magnesium sulfate (MgSO4) IV given twice, before and after cisplatin

21-day cycles; "two patients received more than the standard four courses"

References

  1. Pizzocaro G, Nicolai N, Milani A. Taxanes in combination with cisplatin and fluorouracil for advanced penile cancer: preliminary results. Eur Urol. 2009 Mar;55(3):546-51. Epub 2008 Jul 14. link to original article PubMed